Gynecologic Cancers

Latest News

FDA Grants Priority Review to Pembrolizumab/Chemo in Endometrial Cancer | Image Credit: © freshidea - stock.adobe.com.
FDA Grants Priority Review to Pembrolizumab/Chemo in Endometrial Cancer

February 20th 2024

Data from the phase 3 NRG-GY018 trial support the supplemental biologics license application for pembrolizumab plus chemotherapy as a treatment for those with primary advanced or recurrent endometrial cancer.

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.
EMA Validates Tisotumab Vedotin Marketing Application in Cervical Cancer

February 5th 2024

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.
Pembrolizumab Combo Improves OS in Metastatic Cervical Cancer Subgroups

January 25th 2024

Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent chemotherapy in stage III to IVA cervical cancer.
FDA Approves Pembrolizumab/Chemoradiation in Stage III/IVA Cervical Cancer

January 12th 2024

Tiragolumab Plus Atezolizumab Will Not Be Pursued in Further Cervical Cancer Management
Tiragolumab Plus Atezolizumab Will Not Be Pursued in Further Cervical Cancer Management

January 12th 2024

More News